Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: A randomized study (HAVEN 5)
Background: Emicizumab is a subcutaneously administered humanized, bispecific, monoclonal antibody approved for prophylaxis in people with hemophilia A. Methods: HAVEN 5 (NCT03315455) is a randomized, open-label, phase 3 study of individuals aged ≥12 years with severe hemophilia A without factor VII...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Published: |
2022
|
| Subjects: | |
| Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/74809 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Mahidol University |